Our findings, including those for the BCL-2 and mTOR inhibitors, indicate that there is a need for further <i>in vivo</i> studies to evaluate these drugs as potentially effective treatments for DLBCL of the ABC and GCB subtypes. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.